## Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes


Shayan Fakhraei Lahiji<sup>1,+</sup>, Yoojung Jang<sup>1,+</sup>, Inyoung Huh<sup>1</sup>, Huisuk Yang<sup>1</sup>, Mingyu Jang<sup>1,2</sup>, Hyungil Jung<sup>1,2,\*</sup>

<sup>&</sup>lt;sup>1</sup> Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seoul 03722, Seodaemun-gu, Korea

<sup>&</sup>lt;sup>2</sup> Juvic Inc., Building 102, Yonsei Engineering Research Park, 50 Yonsei-ro, Seoul 03722, Seodaemun-gu, Korea

<sup>\*</sup>Corresponding author: hijung@yonsei.ac.kr Phone: 82-2-2123-2884, Fax: 82-2-362-7265

<sup>&</sup>lt;sup>+</sup>These authors contributed equally to this work.



**Supplementary Figure 1: Viscosity of CMC at different concentrations.** The viscosity of CMC at the concentrations of 4, 8, 10, and 12% (w/v) was measured at the intervals of 200/s. Viscosity is 0.08 Pa.s for 4% CMC, 0.67 Pa.s for 8% CMC, 1.73 Pa.s for 12% CMC, and 3.13 Pa.s for 12% CMC. Increase in the CMC concentration results in increased viscosity.